
Keywords: ترک گروه; AE; Adverse event; BIPN; Bortezomib-induced peripheral neuropathy; C-L; Caspase-like; CFZ; Carfilzomib; ChT-L; Chymotrypsin-like action; IRd; Ixazomib, lenalidomide, and dexamethasone; LG; Leaving group; MM; Multiple myeloma; MTD; Maximum tolerated dose;